JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today hosted its Respiratory Opportunity Meeting for the financial community in New York, featuring in-depth presentations on Teva’s current and future respiratory growth strategy. Teva’s expertise in the respiratory marketplace, combined with the strength of its unique product pipeline, is expected to contribute approximately $2.4 billion to the Company’s overall 2015 targets of $31 billion. Teva intends to file ten products, six of which are new brands, for approval in the U.S. and Europe by 2015, targeting approximately $25 billion in brand value, including new combination products
